Adaptimmune Therapeutics PLC
ADAPY · OTCMCIK 1621227fmd_0GFD7D0NMYM8N8G0RKPRCM52T6Manufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jul 01, 2012 to Jun 30, 2025, 44 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 14 | 38 | 60 | 1 | 4 | 6 | 27 | 60 | 178 |
| Cost of revenue | – | – | – | – | – | – | – | – | 0 |
| Gross profit | – | – | – | – | – | – | – | – | 178 |
| Research and development | 64 | 87 | 98 | 98 | 92 | 111 | 128 | 127 | 149 |
| Selling, general and administrative | – | – | – | – | – | – | 63 | 74 | 87 |
| Operating income | (73) | (81) | (82) | (140) | (133) | (162) | (164) | (140) | (69) |
| Interest expense | – | – | – | – | – | – | – | – | 3 |
| Interest and investment income | 1 | 2 | 3 | 3 | – | – | – | – | – |
| Other non-operating income (expense) | 1 | 9 | (16) | 0 | 1 | 4 | (1) | (1) | (2) |
| Income before taxes | (71) | (70) | (95) | (137) | (130) | (157) | (163) | (113) | (67) |
| Income tax expense | 1 | 0 | 0 | 0 | 0 | 1 | 2 | 1 | 4 |
| Net income from continuing operations | (72) | (70) | (96) | (137) | (130) | (158) | (165) | (114) | (71) |
| Net income | (72) | (70) | (96) | (137) | (130) | (158) | (165) | (114) | (71) |
| Net income to common shareholders | (72) | (70) | (96) | (137) | (130) | (158) | (165) | (114) | (71) |